Windtree's Q3 Loss Widens on Impairment, Debt Costs

TL;DR

**WINTW is burning cash and drowning in debt, making it a high-risk bet on a turnaround that looks increasingly unlikely.**

AI Summary

WINDTREE THERAPEUTICS INC /DE/ reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $(42,761) thousand, a substantial rise from $(4,554) thousand in the prior year. This was primarily driven by a $16,130 thousand impairment of intangible assets and a $(22,402) thousand loss on debt issuances. Revenue remained negligible, with total operating expenses soaring to $27,956 thousand from $20,598 thousand. The company's cash and cash equivalents plummeted from $1,779 thousand at December 31, 2024, to $204 thousand by September 30, 2025. Total assets decreased to $15,983 thousand from $27,875 thousand, while total liabilities more than doubled to $27,584 thousand from $14,698 thousand, largely due to a $9,443 thousand ELOC commitment note payable and $5,089 thousand derivative liability. The strategic outlook includes generating revenue through acquisitions of small companies and their FDA-approved products, as noted in the risk factors.

Why It Matters

This filing reveals a company in a precarious financial state, with a massive increase in net loss and a dwindling cash position. For investors, the significant impairment of intangible assets and rising debt liabilities signal potential long-term value destruction and heightened risk. Employees might face uncertainty given the financial strain, while customers could see delays in product development or commercialization. The broader market should note the challenges faced by small-cap biotech firms in securing and managing financing, especially with the delisting from Nasdaq, which impacts liquidity and investor confidence. The competitive landscape for new FDA-approved products remains fierce, and Windtree's ability to execute its new acquisition strategy is critical.

Risk Assessment

Risk Level: high — The company's cash and cash equivalents dropped from $1,779 thousand to $204 thousand in nine months, indicating severe liquidity issues. A net loss of $(42,761) thousand for the nine months ended September 30, 2025, combined with a $16,130 thousand impairment of intangible assets and a $(22,402) thousand loss on debt issuances, demonstrates significant financial distress and operational challenges.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as the company's financial health has deteriorated significantly with mounting losses and minimal cash. New investors should avoid WINTW until there is clear evidence of a sustainable revenue model and improved liquidity, as the current risk profile is exceptionally high.

Financial Highlights

debt To Equity

N/A

revenue

$0 thousand

operating Margin

N/A

total Assets

$15,983 thousand

total Debt

$27,584 thousand

net Income

$(42,761) thousand

eps

$(1.08)

gross Margin

N/A

cash Position

$204 thousand

revenue Growth

N/A

Key Numbers

• $204 thousand — Cash and cash equivalents (Decreased from $1,779 thousand at December 31, 2024, indicating severe liquidity issues.)
• $(42,761) thousand — Net loss (Increased significantly from $(4,554) thousand for the nine months ended September 30, 2024, highlighting worsening financial performance.)
• $16,130 thousand — Impairment of intangible assets (A major non-cash expense contributing to the increased net loss for the nine months ended September 30, 2025.)
• $(22,402) thousand — Loss on debt issuances (A significant expense for the nine months ended September 30, 2025, reflecting costly financing activities.)
• $27,584 thousand — Total liabilities (More than doubled from $14,698 thousand at December 31, 2024, indicating a substantial increase in financial obligations.)
• $9,443 thousand — ELOC commitment note payable (A major component of current liabilities at September 30, 2025, up from $328 thousand at December 31, 2024.)
• $5,089 thousand — Derivative liability - ELOC commitment note (Increased significantly from $299 thousand at December 31, 2024, reflecting increased financial risk.)
• $15,983 thousand — Total assets (Decreased from $27,875 thousand at December 31, 2024, indicating asset base erosion.)
• 33,708,784 — Common stock outstanding (As of November 14, 2025, indicating significant share dilution from 256,397 shares at December 31, 2024.)
• $(1.08) — Net loss per share attributable to common stockholders (basic and diluted) for Q3 2025 (Significantly lower than $(211.38) for Q3 2024, but this is due to massive share dilution, not improved performance.)

Key Players & Entities

• WINDTREE THERAPEUTICS INC /DE/ (company) — Registrant
• Nasdaq Stock Market (company) — Former listing exchange for Common Stock
• Lee's Pharmaceutical (HK) Ltd. (company) — Licensee of Windtree Therapeutics
• Zhaoke Pharmaceutical (Hefei) Co. Ltd. (company) — Affiliate of Lee's Pharmaceutical (HK) Ltd.
• Varian (company) — Acquired asset
• FDA (regulator) — Approves products
• Private Securities Litigation Reform Act of 1995 (regulator) — Safe-harbor provisions
• Inflation Reduction Act of 2022 (regulator) — Legislation affecting healthcare system
• United States (person) — Country of operation
• People's Republic of China (person) — Country with trade and political tensions

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: Cash and cash equivalents have plummeted from $1,779 thousand at December 31, 2024, to $204 thousand by September 30, 2025. This drastic reduction, coupled with a significant increase in total liabilities to $27,584 thousand from $14,698 thousand, indicates severe liquidity issues and a heightened risk of financial distress.
• Substantial Increase in Debt Obligations [high — financial]: Total liabilities more than doubled to $27,584 thousand, driven by a $9,443 thousand ELOC commitment note payable and a $5,089 thousand derivative liability related to the ELOC. This rapid escalation in debt and associated financial instruments increases financial risk and potential future interest burdens.
• Significant Impairment of Intangible Assets [high — financial]: The company recorded a $16,130 thousand impairment of intangible assets during the nine months ended September 30, 2025. This non-cash charge significantly contributed to the net loss and suggests a potential overvaluation or loss of value in previously recognized intangible assets.
• Costly Debt Issuance Activities [high — financial]: A loss of $22,402 thousand was incurred on debt issuances during the nine months ended September 30, 2025. This indicates that the company is facing very high costs to raise capital through debt, potentially due to its financial condition or market perception.
• Erosion of Asset Base [medium — operational]: Total assets decreased from $27,875 thousand at December 31, 2024, to $15,983 thousand by September 30, 2025. This decline, particularly the $16,130 thousand impairment of intangible assets, points to a shrinking operational or investment base.
• Massive Share Dilution [medium — financial]: Common stock outstanding increased from 256,397 shares at December 31, 2024, to 33,634,221 shares by September 30, 2025. This massive dilution significantly impacts the net loss per share, masking the underlying operational performance deterioration.
• Dependence on Acquisitions for Revenue [medium — market]: The strategic outlook relies on generating revenue through acquisitions of small companies and their FDA-approved products. This strategy carries inherent risks related to integration, market acceptance, and the successful commercialization of acquired assets.
• Worsening Net Loss [high — financial]: The net loss for the nine months ended September 30, 2025, surged to $(42,761) thousand from $(4,554) thousand in the prior year. This substantial increase highlights a deteriorating financial performance, exacerbated by significant one-time charges.

Industry Context

Windtree Therapeutics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face long development cycles, significant regulatory hurdles, and the need for substantial funding. Success typically hinges on the development and commercialization of novel therapeutics, often requiring strategic partnerships or acquisitions to scale.

Regulatory Implications

As a biotechnology company, Windtree Therapeutics is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in regulatory policy can significantly impact development timelines and market access. The company's strategy of acquiring FDA-approved products suggests a focus on navigating these regulatory pathways.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Evaluate the success of the acquisition strategy.
3. Assess the impact of share dilution on existing shareholders.
4. Analyze the sustainability of the current operational model.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a net loss of $(42,761) thousand, a significant increase from the prior year, driven by impairments and debt issuance costs. Cash reserves dwindled to $204 thousand, and liabilities more than doubled.
• 2024-12-31: As of December 31, 2024 — Company had $1,779 thousand in cash and cash equivalents and total liabilities of $14,698 thousand, providing a baseline for the subsequent deterioration.

Glossary

ELOC commitment note payable

A note payable representing a commitment to provide or receive funds under an Equity Line of Credit (ELOC). This indicates a financing arrangement where the company has access to funds up to a certain limit. (A significant component of current liabilities, increasing from $328 thousand to $9,443 thousand, indicating increased reliance on this financing facility and associated obligations.)

Derivative liability - ELOC commitment note

A liability arising from financial instruments whose value is derived from an underlying asset or benchmark, in this case, related to the ELOC commitment note. It often reflects the fair value of options or other embedded derivatives within the financing agreement. (Increased substantially from $299 thousand to $5,089 thousand, suggesting increased financial risk and complexity associated with the ELOC financing.)

Impairment of intangible assets

A charge taken when the carrying value of an intangible asset (like patents, trademarks, or goodwill) on the balance sheet is deemed to be higher than its recoverable amount, indicating a loss in value. (A major non-cash expense of $16,130 thousand for the nine months ended September 30, 2025, significantly contributing to the increased net loss.)

Loss on debt issuances

Expenses incurred when issuing debt, which can include underwriting fees, discounts, and the fair value of warrants or other features attached to the debt. A negative impact on net income. (A substantial $(22,402) thousand loss for the nine months ended September 30, 2025, highlighting the high cost of capital for the company.)

Mezzanine equity

A class of equity that has characteristics of both debt and equity, often featuring redemption rights or preferred dividend rights. It sits between senior debt and common equity in the capital structure. (Decreased from $3,181 thousand to $9 thousand, primarily due to the redemption or conversion of preferred stock, impacting the overall equity structure.)

Accumulated deficit

The total cumulative net losses of a corporation since its inception that have not been offset by net income. It represents a reduction in retained earnings. (Increased from $(846,610) thousand to $(889,371) thousand, reflecting the ongoing net losses of the company.)

Common stock outstanding

The total number of shares of common stock that have been issued and are held by investors. (Experienced a dramatic increase from 256,396 shares to 33,634,220 shares, indicating significant share issuance and dilution.)

Year-Over-Year Comparison

Compared to the prior year period ending September 30, 2024, Windtree Therapeutics has experienced a severe deterioration in its financial condition. The net loss has widened dramatically from $(4,554) thousand to $(42,761) thousand, primarily due to a $16,130 thousand impairment of intangible assets and a $(22,402) thousand loss on debt issuances. Total liabilities have more than doubled, while cash and cash equivalents have plummeted, indicating a critical liquidity crunch. Furthermore, the company has undergone massive share dilution, increasing common stock outstanding by over 130 times, which significantly impacts per-share metrics.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value WINT OTCID Indicate by
• $156 — ELOC sales, net of issuance costs of $156 - - - - - - - 29 - 4,371 - - - 4,371

Filing Documents

• wint20250930_10q.htm (10-Q) — 2396KB
• ex_890835.htm (EX-4.4) — 58KB
• ex_890836.htm (EX-4.5) — 121KB
• ex_857258.htm (EX-31.1) — 15KB
• ex_857259.htm (EX-32.1) — 7KB
• 0001437749-25-035751.txt ( ) — 9969KB
• wint-20250930.xsd (EX-101.SCH) — 84KB
• wint-20250930_cal.xml (EX-101.CAL) — 46KB
• wint-20250930_def.xml (EX-101.DEF) — 603KB
• wint-20250930_lab.xml (EX-101.LAB) — 496KB
• wint-20250930_pre.xml (EX-101.PRE) — 629KB
• wint20250930_10q_htm.xml (XML) — 1393KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Page Item 1.

Financial Statements

Financial Statements 4 CONDENSED CONSOLIDATED BALANCE SHEETS 4 As of September 30, 2025 (unaudited) and December 31, 2024 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) 5 For the Three and Nine Months Ended September 30, 2025 and 2024 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (unaudited) For the Three and Nine Months Ended September 30, 2025 and 2024 6 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) 8 For the Nine Months Ended September 30, 2025 and 2024 Notes to Condensed Consolidated Financial Statements (unaudited) 9 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 38 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 51 Item 4.

Controls and Procedures

Controls and Procedures 51

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 53 Item 1A.

Risk Factors

Risk Factors 53 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55 Item 3. Defaults Upon Senior Securities 56 Item 4. Mine Safety Disclosures 56 Item 5. Other Information 56 Item 6. Exhibits 58

Signatures

Signatures 60 1 Table of Contents Unless the context otherwise requires, all references to "we," "us," "our," and the "Company" include Windtree Therapeutics, Inc., and its consolidated subsidiaries. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements provide our current expectations or forecasts of future events and financial performance and may be identified by the use of forward-looking terminology, including such terms as "anticipates," "believes," "contemplates," "continues," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "targets," or "will" or, in each case, their negative, or other variations or comparable terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Examples of such risks and uncertainties, which potentially could have a material adverse effect on our development programs, business and/or operations, include, but are not limited to the following: our estimates regarding future results of operations, financial position, research and development costs, capital requirements, and our needs for additional fin

Financial Statements

ITEM 1. Financial Statements WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 204 $ 1,779 Prepaid expenses and other current assets 1,198 795 Note receivable, net 5,803 - Total current assets 7,205 2,574 Property and equipment, net 61 111 Restricted cash 10 9 Operating lease right-of-use assets 707 1,051 Intangible assets 8,000 24,130 Total assets $ 15,983 $ 27,875 LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,651 $ 1,879 Accrued expenses 2,007 1,706 Operating lease liabilities - current portion 544 508 Convertible notes payable 2,590 - ELOC commitment note payable 9,443 328 Derivative liability - ELOC commitment note 5,089 299 Common stock warrant liability 2 305 Loans payable 111 333 Other current liabilities 464 359 Total current liabilities 21,901 5,717 Operating lease liabilities - non-current portion 240 653 Other liabilities 3,800 3,800 Deferred tax liabilities 1,643 4,528 Total liabilities 27,584 14,698 Mezzanine equity: Series B redeemable preferred stock, $ 0.001 par value; 5,500 shares authorized; 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively - - Series C redeemable preferred stock, $ 0.001 par value; 18,820 shares authorized; 6 and 11,757 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 4 3,181 Series D redeemable preferred stock, $ 0.001 par value; 5,000 shares authorized; 4 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 5 - Total mezzanine equity 9 3,181 Stockholders' equity: Preferred stock, $ 0.001 par value; 4,970,680 shares authorized; 0 shares issued and outstan

View Full Filing

View this 10-Q filing on SEC EDGAR